Session » Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II (1565–1583)

Date: Tuesday, November 9, 2021

Time: 8:30AM-10:30AM

Meeting: ACR Convergence 2021

8:30AM-10:30AM: Abstract Number: 1570

AR882, a Novel Uricosuric Agent, Exhibited Favorable Pharmacokinetic Profile and Balanced Excretion and Metabolic Pathways in a Human AME Study

8:30AM-10:30AM: Abstract Number: 1568

AR882, a Potent and Selective Uricosuric Agent, Showed Effectiveness in Patients with Various Degrees of Renal Impairment

8:30AM-10:30AM: Abstract Number: 1565

Causal Mediation Analysis of the Relationship of Canakinumab’s Protective Effect Against Gout Flares and High-sensitivity C-reactive Protein in the CANTOS Trial

8:30AM-10:30AM: Abstract Number: 1574

Comparison of Urate Quantification in Gout and Asymptomatic Hyperuricemia by Ultrasound and Dual Energy Computed Tomography

8:30AM-10:30AM: Abstract Number: 1583

Creation of an Ultrasonographic Scoring System for CPPD Extent: Results from a Delphi Process by the OMERACT US Working Group – CPPD Subgroup

8:30AM-10:30AM: Abstract Number: 1576

Development of a Plain Radiographic Scoring System for New Bone Formation in Gout

8:30AM-10:30AM: Abstract Number: 1582

Diagnostic Accuracy and Reliability of Conventional Radiography of the Knee in Calcium Pyrophosphate Deposition Disease by Using New Definitions: An Ancillary Study of the OMERACT Ultrasound – CPPD Group

8:30AM-10:30AM: Abstract Number: 1569

Effect of Elevated Serum Urate on Kidney Function: Analysis of a Randomized Controlled Trial of Inosine Supplementation

8:30AM-10:30AM: Abstract Number: 1571

Elevated Lactate, Procalcitonin Levels and SIRS (Systemic Inflammatory Response Syndrome) in a Subset of Patients with Gout

8:30AM-10:30AM: Abstract Number: 1581

Genetic Effects on the Transition from Hyperuricemia to Gout

8:30AM-10:30AM: Abstract Number: 1566

Hyperuricemia Is Associated with Vascular Endothelial Dysfunction – the Impact of Hyperuricemia on Flow Mediated and Nitroglycerin Mediated Dilatation of the Brachial Artery

8:30AM-10:30AM: Abstract Number: 1577

Interleukin-37: Associations of Plasma Levels and Genetic Variants in Gout

8:30AM-10:30AM: Abstract Number: 1578

NLRP3 Inflammasome Pathway Expression at Atheroma Plaques from Peripheral Artery Disease According to the Uricemic Status

8:30AM-10:30AM: Abstract Number: 1567

Pharmacokinetics and Pharmacodynamics of Anthocyanins After Oral Administration of Oral Tart Cherry Juice Concentrate to Gout Patients

8:30AM-10:30AM: Abstract Number: 1579

Phenome-Wide Association of Gout Risk Loci

8:30AM-10:30AM: Abstract Number: 1572

Ultrasound Signs of Gout in a Population with Asymptomatic Hyperuricemia

8:30AM-10:30AM: Abstract Number: 1575

Urate Crystals Regulate a Distinct JNK-Dependent Metabolic and Inflammatory Response

8:30AM-10:30AM: Abstract Number: 1573

Vascular Monosodium Urate Crystal Deposition in Gout: A Dual-energy CT and Microscopy Study of Cadaveric Donors

8:30AM-10:30AM: Abstract Number: 1580

Whole Blood Gene Expression and eQTL Analysis Implicate GGT7 and FADS2 in Gout Pathogenesis

« View all sessions from this meeting